Listed by the USPTO as BURKHART, MICHAEL D
Tech Center 1600 • Art Units: 1633 1638 1653
This examiner grants 62% of resolved cases
This examiner is in Tech Center 1600 and Art Unit 1633, with 850 resolved cases. The allowance rate is 62.5%, and the median time to allowance is 1217 days. The 11.8% interview lift is positive but limited, suggesting that interviews are a useful supplement rather than the principal driver of outcomes.
The recorded companies are Hoffmann-La Roche Inc., Intellia Therapeutics Inc., and Ucl Business Ltd. The leading firms are LEYDIG VOIT & MAYER, LTD, Acuity Law Group, P.C., and ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP. Practitioners may emphasize precise written claim positioning and reserve interviews for targeted clarification.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17777741 | COMPOSITIONS AND METHODS OF USING ENGINEERED FUSION PROTEINS THAT BIND G4C2 HUMAN REPEATS | Non-Final OA | The Regents of the University of California |
| 17559934 | METHOD FOR THE PRODUCTION OF AN ANTIBODY | Final Rejection | Hoffmann-La Roche Inc. |
| 18670684 | Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18282061 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRHYTHMOGENIC CARDIOMYOPATHY | Final Rejection | UCL BUSINESS LTD |
| 18628222 | METHODS FOR GENERATION OF PODOCYTES FROM PLURIPOTENT STEM CELLS AND CELLS PRODUCED BY THE SAME | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18915595 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS | Non-Final OA | Purdue Research Foundation |
| 19061415 | Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.5% of resolved applications examined by Michael D Burkhart were allowed (850 resolved cases), compared with 34.9% across Art Unit 1633 over the last five years.
This examiner's interview lift is +11.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Michael D Burkhart took 1,217 days on average from filing to allowance.
Michael D Burkhart examines applications in Art Unit 1633 in Tech Center 1600 (Biotechnology & Pharmaceuticals).